Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why do you make it sound like this can’t be a top 3 covid treatment? It absolutely can. All it takes is a eua for decreasing number of patients requiring ventilation.
The problem with investors that don't have a scientific background is they have no idea the amount of work and coordination required to pull off small trials, let alone major international ones:
Here is why Algernon deserves BIG CREDIT:
I agree, it's the data readout is the most important of all, however, a few things remains true in pharma land:
1) It is an incredible amount to set up a clinical trial for a drug as it takes ethics approvals, government approvals, meeting safety milestones in the trial, and requires a significant coordinated initiative across many institutions and with many individuals/doctors/research associates involved. The protocol writing, each hospital passing ethics and enrolling patients and collecting data. ITS IMMENSE WORK.
Many people who invest have no idea the amount of work that goes on behind the scenes, they just go online and demand results. Small companies that pull off big trials have EARNED RESPECT NO MATTER THE RESULT OF THE TRIAL.
FACT: These guys have earned MASSIVE respect for pulling off one of the most incredible COVID trials to date.
2) Finding signal is like hitting the jackpot. It's completely out of the companies control. It has nothing to do with Algernon. They picked a drug that scientifically and mechnistically SHOULD WORK. Whether it ACTUALLY works is out of their control.
FACT: They don't control the signal. They just pick the drug that SHOULD work and hope for the best. And that they have done. Wonderfully.
3) They can't guarantee a trial will be successful... like I said, it's out of their control... so they MUST prepare to be one step ahead moving forward so investors and the company aren't left in a dead period between releasing COVID results and the next drug they investigate.
FACT: They deserve credit for thinking ahead and being one step ahead of the game. THEY ARE RELENTLESS. MARK IS A BEAST...
AMG, stay strong and let's stay positive
Very well thought through, logical, great scientific explanation... this is the type of stuff we have been waiting for!
Wow this news release is actually incredible! Some nice science and well thought out! And the good PR to go with it... I’m impressed!!!
in the words of the wise zack morris - buy the dips and sell the rips ... the dip here is done .. next spike is coming
but yes, agreed re: long position... need to see the data which is coming soon
Stocks held well in the 20's (Canadian); on the way up from here
I agree with comments regarding the shi* PR. However, whats going to make us $ is the signal they say they've found re: less pts requiring intubation... spike is coming... it's just time my friend...
Perhaps we just need a short squeeze aha
perhaps .... but TBH, nothing matters aside from the results of the trial... scientific results and the clinical impact triumph over all other factors... reduce the number of patients going on to require ventilation and get EUA and this is instantly sky rocketing...
WHO ordinal scores are not a good endpoint for COVID trials. I think when we see the results of the final data analysis from the ifenprodil Phase 2, the value is going to be in all of the other endpoints. If there is a signal in decreasing time to ventilation, this could get EUA and the company will hit the jackpot
The mechanism of Ifendprodil does modulate the immune response but it is not an anti viral. Works through different mechanism involving NMDA receptor and possibly sigma receptor. Either way, decreases cytokine storm in lungs and likely decreases microvascular permeability
Virus definitely not going anywhere, mutating strains expected and need for recurrent vaccination (yes, more than once in your lifetime) likely given potential for waning immunological response and virus mutation...
Translation: we need treatments like ifenprodil in addition to vaccines
Hopefully they get an EUA pertaining to helping patients stay off a ventilator, as the initial data has suggested is likely
They don’t need 10 million to run a trial .... they need a fraction of that ... now that they have an additional 2 million they should be covered
My prediction is that they get EUA based on time to ventilation
As a scientist I am interested in the data. But to be honest, the biggest driver for the SP once phase 3 begins and the real possibility of EUA is looming, will be the national attention this receives. There are just so few Phase 3 trials out there its going to drive a massive spike.
Regardless of all the BS releases they put out.
I strongly believe they will use the 'time to ventilation' endpoint in Phase 3. That is ideal. This will set them up for success. Early success will lead to securing EUA. They secure EUA, we get rich.
They have 2 million now at least, we are probably good to go.
I agree with you, there are numerous endpoints we haven't heard about yet, but they have told us what they think is most promising. So at least until we hear about the remainder of the readout, I would assume full steam ahead with ventilator as the primary for Phase 3.
maybe 2 million is enough $ and we don't have to worry about a PP
Given how these guys pump, my guess is that any hint of a deal would be made apparent ... my guess is dilution
I might be wrong but sure as h*ll don't think so, having 8 years experience watching this group of individuals
you cant compare a animal study to a human study
They are going to have to raise capital for the phase 3... it's coming soon
The news today meant nothing. These guys continue to pump. It's common knowledge that when the data safety monitoring board approves the trial half way in to phase 2, it's clearly safe. We already know ifenprodil is safe its been used for other conditions for years.
Their news release today reaffirms my point they are pumping out garbage PR... that's why it's hard to take them seriously. That's why I am upset.
"They call this a green light"... if we knew the drug is safe, what exactly does this news tell us? Anything new? No. It's two paragraphs of pump to try and prevent the day traders from getting bored.
They pump the stock a bit and then... where is the money coming from? That's coming next...
The company has already shown us most of the data, so there isn't any "discovering" to be done. You know what the result show for *most* of the patients. They showed MORE data than they said they would, which is a classic sign of them trying to improve the power to generate a signal because they were struggling to find one with fewer patients.
I agree. We must invest in the science. My issue currently is with how they are doing business, pumping and dumping the stock with weak press releases and paying themselves way too much money for a company that continually dilutes and has no revenues...
Agreed. And if they are reading this, then here's a msg:
1. Chill on the Bull S*it PR
....
Do you understand how stupid this PR is?
These guys are saying they identified a third party journal article, published in a crap no name journal, from some random scientist in Japan and most importantly...
THEY ARE SAYING THEY FOUND A STUDY SUGGESTING IFENPRODIL SHOULD WORK FOR COVID BASED ON LAB STUDIES... WHO GIVES A F... THEY JUST DID THE REAL HUMAN STUDY AND IT WAS A LET DOWN...
Do people not understand this? It's like GOING BACKWARDS. Who F'ing cares about the lab study. They did they f'ing real deal human study.
This has absolutely ZERO impact in the company matters. Zero impact on shareholder value. Zero impact on the results of the real f'ing trial they just ran. Furthemore, it's probably just Mark Williams sneaky way of trying to divert attention to maybe take your mind off the fact it didn't work for NMDA and say hey we found a new line of work.
The whole Biopub conflict of interest is BS to TBH
but yes, i agree, these guys need to get their PR BS together
Are they pumping and dumping this? Look at this PR.
They have basically just said:
(1) we are struggling to enroll for one of our studies
(2) we need other options
(3) "if the data is positive" ??? You have the data. You have seen most of the data.... you getting a hype vibe?
Intentional?
The current (or longstanding?) problems here is both financial and leadership-based (noting that leadership is DOING THE RIGHT THINGS):
1) More dilution is coming because they don't have the money to run phase 3 (from what I can tell). The cycle of life in penny land, not surprising. where will the money come from you ask?
2) the guys at the helm are paying themselves like kings despite the fact the company has no revenues and this, like many other penny lands stocks, should not be publicly traded because these guys are taking the money of the investor and putting it in their pocket, offering the investor PROMISES of big gains.
3)the guys at the helm are playing a PR game which involves pumping and dumping the SP. I mean this stock has been a ROLLER COASTER ride. It's nauseating. My patience is thin, but bear with me... my point is attested to by the recent flop news release which did not spin things in the correct light. That followed up by Williams going on air saying "don't worry, we still have IPF" thereby basically announcing COVID trial isn't what he expected
I mean come on...
You and I have been here a long time. I am invested in the science. These guys are letting us down on the PR. Salty taste here... because they fumbled the PR and it feels almost purposeful. Roller coaster of SP all these years.
So this only covers IPF, not all respiratory disease
These guys are getting paid WAY too much money given that they are not generating revenues it's absolutely criminal.
honestly who knows at this point
Where’s the funding coming from moving forward short term
Will get manipulated again? This is getting manipulated in front of your (our) eyes. Time for everyone to wake up to the fact that this group of companies is playing game after game. They didn’t need to halt. They didn’t need to word things like they did and play catch up a couple days later. This is all thought out. Time for a wake up call. Maybe I shouldn’t be long. Maybe I should ride the roller coaster?
Private placement coming to a PR news release near you?
If there’s no change found in the data set they just presented, which included the majority of their patients, They won’t find change after adding the remaining 20-30 patients
Yeah, to let it drop after it spiked. Run it down. Surely they will run it up again